THOP1 and sarcoma: Since the clinical applicability of this route of administration was questionable and information on THOP1-related sensitivity was lacking, we further investigated intravenous administration of both CBR-049 and CBR-050 (another CoBioRes lead molecule) in 10 THOP1-expressing sarcoma xenograft models.